CRISM Therapeutics said on Thursday it has begun patient recruitment for a Phase II clinical trial evaluating its ChemoSeed product for the treatment of glioblastoma, a form of brain cancer.
The London-based company, which trades on the AIM market under the ticker CRTX, activated its first clinical site and opened the study for enrollment, enabling investigators to screen and enroll eligible patients. The trial marks a key milestone for CRISM’s ChemoSeed program, a localized chemotherapy delivery system designed to target residual tumor tissue following surgical resection.
CRISM’s Chief Scientific Officer, Professor Christopher McConville, described the activation of the first clinical site as an important step for the company and its ChemoSeed initiative. The product delivers irinotecan directly into the tumor resection margin during surgery, when residual tumor burden is at its lowest, according to Professor Garth Cruickshank, Emeritus Professor of Neurosurgery at the University of Birmingham and a member of CRISM’s Scientific Advisory Board.
The Phase II study will assess the safety and efficacy of ChemoSeed in patients with glioblastoma. CRISM plans to provide an update once the first patient has been treated. The announcement was classified as inside information under the EU Market Abuse Regulation, as incorporated into UK law.
